Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0BLHTP
ADC Name	Cetuximab-Comound (Ia)
Synonyms	Cetuximab Comound (Ia) Click to Show/Hide
Organization	Orum Therapeutics, Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Synovial sarcoma [ICD11:2B5A] Investigative
Drug-to-Antibody Ratio	8
Structure
	3D MOL	2D MOL
Antibody Name	Cetuximab		Antibody Info
Antigen Name	Epidermal growth factor receptor (EGFR)		Antigen Info
Payload Name	NeoDegrader P1		Payload Info
Therapeutic Target	Protein cereblon (CRBN)		Target Info
Linker Name	Cetuximab-Comound (Ia) linker

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.66	pM	Aska-SS cells	Biphasic synovial sarcoma
Half Maximal Inhibitory Concentration (IC50)	10.57	pM	HS-SY-2 cells	Monophasic synovial sarcoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.66 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Biphasic synovial sarcoma	Aska-SS cells		CVCL_6C43
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10.57 pM	Positive EGFR expression (EGFR+++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Monophasic synovial sarcoma	HS-SY-2 cells		CVCL_8719

References

Ref 1	Neodegrader conjugates; 2021-10-07.